PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16858347-7 2006 Treatment of men with ischemic heart disease with rosuvastatin (10 mg for 3 months) led to achievement of target values of LDLCH in 77% of them, to significant lowering of concentrations of CRP and interleukin 6, and to improvement of endothelial function. Rosuvastatin Calcium 50-62 interleukin 6 Homo sapiens 198-211 35173877-1 2022 OBJECTIVES: This prospective study aimed to explore the effects of various doses of rosuvastatin on the hemodynamic changes, highly sensitive C-reactive protein (hs-CRP) and interleukin-6 (IL-6) levels in elderly patients with unstable angina pectoris. Rosuvastatin Calcium 84-96 interleukin 6 Homo sapiens 174-187 35173877-1 2022 OBJECTIVES: This prospective study aimed to explore the effects of various doses of rosuvastatin on the hemodynamic changes, highly sensitive C-reactive protein (hs-CRP) and interleukin-6 (IL-6) levels in elderly patients with unstable angina pectoris. Rosuvastatin Calcium 84-96 interleukin 6 Homo sapiens 189-193 32652935-14 2020 Follow-up after 6 months of rosuvastatin therapy showed a significantly greater reduction in hs-CRP and IL-6 levels in the CAE-A group than in the CAE-B group, which again were greater in the CAE-B group than in the CAE-C group. Rosuvastatin Calcium 28-40 interleukin 6 Homo sapiens 104-108 33913752-0 2021 The Effect of Rosuvastatin on plasma/serum levels of high sensitivity C-reactive protein, Interleukin-6 and D-dimer in people living with Human Immunodeficiency Virus: a systematic review and meta-analysis. Rosuvastatin Calcium 14-26 interleukin 6 Homo sapiens 90-103 32955957-6 2021 After 12 months, rosuvastatin produced a significant decrease in mean serum levels of hsCRP (-0.28 mg/dL; p = .037), IL-6 (-2.1 pg/mL; p = .018) and TNF-alpha (-6.3 pg/mL; p = .004) in patients with MetS. Rosuvastatin Calcium 17-29 interleukin 6 Homo sapiens 117-121 27739345-0 2017 Rosuvastatin Inhibits Interleukin (IL)-8 and IL-6 Production in Human Coronary Artery Endothelial Cells Stimulated With Aggregatibacter actinomycetemcomitans Serotype b. Rosuvastatin Calcium 0-12 interleukin 6 Homo sapiens 45-49 27846790-4 2017 FINDINGS: Administration of ROS and ATO both significantly reduced the concentrations of TC, LDL-C, TG, hs-CRP, and IL-6, but increased high-density lipoproteincholesterol (HDL-C), ALB, PA, and TF levels. Rosuvastatin Calcium 28-31 interleukin 6 Homo sapiens 116-120 27739345-9 2017 Aa-induced IL-6 and IL-8 production was inhibited by rosuvastatin, particularly at higher doses. Rosuvastatin Calcium 53-65 interleukin 6 Homo sapiens 11-15 27739345-10 2017 Interestingly, reduced IL-6 and IL-8 levels were observed in HCAECs stimulated with Aa in the presence of higher concentrations of rosuvastatin. Rosuvastatin Calcium 131-143 interleukin 6 Homo sapiens 23-27 26278425-9 2015 RESULTS: Rosuvastatin lowered IL-6 levels at T4, T5 and T6 time points (T4, T5, T6 p < 0.05), and elevated IL-10 levels at T3 and T4 (T3, T4 p < 0.05). Rosuvastatin Calcium 9-21 interleukin 6 Homo sapiens 30-34 26687339-9 2016 RESULTS: The combination of ezetimibe plus rosuvastatin decreased total cholesterol, low-density lipoprotein cholesterol, hsCRP, IL-6, and MMP-9 levels at six and 12 months after treatment. Rosuvastatin Calcium 43-55 interleukin 6 Homo sapiens 129-133 25495178-7 2015 Rosuvastatin therapy was associated with a reduction in hsCRP (-20% vs. 11%, P = 0.017) and an attenuation of the rise in IL6 concentration (8% vs. 30%, P = 0.028) compared with placebo. Rosuvastatin Calcium 0-12 interleukin 6 Homo sapiens 122-125 24410968-6 2014 In the CRP-transgenic strain, we found that rosuvastatin treatment decreased circulating levels of inflammatory response markers IL6 and TNFalpha without decreasing circulating levels of human CRP. Rosuvastatin Calcium 44-56 interleukin 6 Homo sapiens 129-132 25319951-6 2014 RESULTS: Compared with placebo, rosuvastatin treatment significantly reduced the incidence of periprocedural myocardial infarction (PMI) and levels of cardiac troponin I (cTnI) associated with decreased relative expression of serum miR-155, levels of inflammatory cytokines (INF-gamma, TNF-alpha, and IL-6), increased SHIP-1 expression and CD4(+)FoxP3(+)Treg percentage values (P < 0.05). Rosuvastatin Calcium 32-44 interleukin 6 Homo sapiens 301-305 25771851-9 2015 Levels of inflammatory measures, TNF-alpha, IL-6 and ICAM-1 decreased significantly (p < 0.01) after treatment with rosuvastatin. Rosuvastatin Calcium 119-131 interleukin 6 Homo sapiens 44-48 25771851-12 2015 Significant negative correlation was observed between FMD and IL-6, ICAM-1, CRP after treatment with rosuvastatin. Rosuvastatin Calcium 101-113 interleukin 6 Homo sapiens 62-66 25771851-14 2015 Rosuvastatin lowers the proinflammatory cytokines, especially IL-6 and TNF-alpha, which downregulates adhesion molecules and CRP production which in turns improves ED. Rosuvastatin Calcium 0-12 interleukin 6 Homo sapiens 62-66 23364255-9 2013 Plasma levels of hs-CRP, IL-6, and MCP-1 increased significantly after PCI in both the rosuvastatin and control groups; however, the postprocedural elevations in hs-CRP and IL-6 levels were significantly lower in the rosuvastatin group than the control group. Rosuvastatin Calcium 87-99 interleukin 6 Homo sapiens 173-177 23364255-10 2013 CONCLUSIONS: A single, high dose (20 mg) of rosuvastatin prior to PCI reduces postprocedural myocardial injury in patients with ACS, with a concomitant attenuation of the postprocedural increase in hs-CRP and IL-6 levels. Rosuvastatin Calcium 44-56 interleukin 6 Homo sapiens 209-213 22555227-1 2012 The aim of this study was to study the effects of rosuvastatin in patients with rheumatoid arthritis (RA) looking at the C-reactive protein (CRP), interleukin-6 (IL-6) and joint disease activity. Rosuvastatin Calcium 50-62 interleukin 6 Homo sapiens 147-160 22999910-0 2013 Rosuvastatin inhibits spontaneous and IL-1beta-induced interleukin-6 production from human cultured osteoblastic cells. Rosuvastatin Calcium 0-12 interleukin 6 Homo sapiens 55-68 22999910-4 2013 The aim of the study was to evaluate the effect of rosuvastatin on IL-6 production by human osteoblasts. Rosuvastatin Calcium 51-63 interleukin 6 Homo sapiens 67-71 22999910-8 2013 RESULTS: Rosuvastatin significantly reduced IL-6 levels in the osteoblast culture medium, both in unstimulated and IL-1beta-stimulated cells. Rosuvastatin Calcium 9-21 interleukin 6 Homo sapiens 44-48 22999910-12 2013 CONCLUSION: Our results show that rosuvastatin decreases IL-6 production by osteoblasts, thereby suggesting a possible inhibiting activity on osteoclast function in an indirect way. Rosuvastatin Calcium 34-46 interleukin 6 Homo sapiens 57-61 22555227-1 2012 The aim of this study was to study the effects of rosuvastatin in patients with rheumatoid arthritis (RA) looking at the C-reactive protein (CRP), interleukin-6 (IL-6) and joint disease activity. Rosuvastatin Calcium 50-62 interleukin 6 Homo sapiens 162-166 22555227-9 2012 IL-6 showed a trend towards worsening in the rosuvastatin group (+0.15; SD, 1.09) compared with placebo (-0.73; SD, 1.4); P value, 0.054. Rosuvastatin Calcium 45-57 interleukin 6 Homo sapiens 0-4 18789009-6 2008 Treatment with rosuvastatin in moderate doses significantly suppressed activity of endogenous inflammation and oxidative stress by way of activation of antioxidant system of plasma, decrease of oxidation of fractions of lipoproteins, suppression of " nitrotirosine " stress, as well as partial inhibition of efficacy of action of secretory phospholipase A2, lowering of content of C-reactive protein and interleukin-6. Rosuvastatin Calcium 15-27 interleukin 6 Homo sapiens 404-417 22555227-10 2012 These data show that rosuvastatin with might decrease the CRP independent to IL-6 in patients with RA but does not improve the overall rheumatoid disease activity. Rosuvastatin Calcium 21-33 interleukin 6 Homo sapiens 77-81 17595889-0 2007 Rosuvastatin reduces interleukin-6-induced expression of C-reactive protein in human hepatocytes in a STAT3- and C/EBP-dependent fashion. Rosuvastatin Calcium 0-12 interleukin 6 Homo sapiens 21-34 18082089-7 2007 Pharmacological treatment with either rosuvastatin or metformin lead to reductions in IL-6, TNFalpha, GSH and GPx levels and an increase in the SOD level, and there were significant interactions between the two treatment groups for these variables. Rosuvastatin Calcium 38-50 interleukin 6 Homo sapiens 86-90 17595889-3 2007 METHODS: Interleukin 6 (IL-6) stimulated human hepatoma cells (Hep3B) and primary human hepatocytes (PHH) were incubated with various concentrations of rosuvastatin (0.3 - 1 microM) for 24 hours. Rosuvastatin Calcium 152-164 interleukin 6 Homo sapiens 24-28 17595889-12 2007 CONCLUSIONS: Our results show a direct inhibitory effect of rosuvastatin on IL-6-induced expression of CRP in liver cells. Rosuvastatin Calcium 60-72 interleukin 6 Homo sapiens 76-80 17577102-7 2007 Rosuvastatin inhibited the expressions of ICAM-1, MCP-1, IL-8, IL-6, and COX-2 mRNA and protein levels. Rosuvastatin Calcium 0-12 interleukin 6 Homo sapiens 63-67 18260902-5 2007 IL-6 and CRP serum levels were also decreased after rosuvastatin therapy. Rosuvastatin Calcium 52-64 interleukin 6 Homo sapiens 0-4